NCT07511218

A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AHB - 171 Injection in Healthy Participants (HP) and Chronic Hepatitis B(CHB) Participants

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 110 (estimated)
• Sponsor: Ausper Biopharma Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of AHB-171 Injection in healthy participants (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in CHB participants.

Conditions

• Chronic Hepatitis B Infection

Interventions

Type	Name	Description
DRUG	AHB-171 Injection	AHB-171 Injection is adminstrated via subcutaneous injection
DRUG	Placebo	Placebo is admistrated via subcutaneous injection
DRUG	Nucleos(t)ide Analogue (NA)	Oral administration

Timeline

• Start date: 2026-04-15
• Primary completion: 2027-12-30
• Completion: 2028-06-30
• First posted: 2026-04-06
• Last updated: 2026-04-06

Locations

1 site across 1 country: China